vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and B&G Foods, Inc. (BGS). Click either name above to swap in a different company.
B&G Foods, Inc. is the larger business by last-quarter revenue ($439.3M vs $247.1M, roughly 1.8× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -4.4%, a 15.5% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -4.7%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-70.7M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -12.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
B&G Foods, Inc. is an American branded foods holding company based in Parsippany, New Jersey. The company was formed in 1996 to acquire Bloch & Guggenheimer, a Manhattan-based producer of pickles, relish and condiments which had been founded in 1889.
ANIP vs BGS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $439.3M |
| Net Profit | $27.5M | $-19.1M |
| Gross Margin | — | 22.5% |
| Operating Margin | 14.1% | 2.5% |
| Net Margin | 11.1% | -4.4% |
| Revenue YoY | 29.6% | -4.7% |
| Net Profit YoY | 367.5% | -356.5% |
| EPS (diluted) | $1.14 | $-0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | — | ||
| Q3 25 | $227.8M | $439.3M | ||
| Q2 25 | $211.4M | $424.4M | ||
| Q1 25 | $197.1M | $425.4M | ||
| Q4 24 | $190.6M | $551.6M | ||
| Q3 24 | $148.3M | $461.1M | ||
| Q2 24 | $138.0M | $444.6M | ||
| Q1 24 | $137.4M | $475.2M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $-19.1M | ||
| Q2 25 | $8.5M | $-9.8M | ||
| Q1 25 | $15.7M | $835.0K | ||
| Q4 24 | $-10.3M | $-222.4M | ||
| Q3 24 | $-24.2M | $7.5M | ||
| Q2 24 | $-2.3M | $3.9M | ||
| Q1 24 | $18.2M | $-40.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | 22.5% | ||
| Q2 25 | — | 20.5% | ||
| Q1 25 | — | 21.2% | ||
| Q4 24 | — | 21.5% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | 20.7% | ||
| Q1 24 | — | 22.9% |
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | 2.5% | ||
| Q2 25 | 6.6% | 5.2% | ||
| Q1 25 | 13.3% | 8.4% | ||
| Q4 24 | -2.3% | -46.6% | ||
| Q3 24 | -13.8% | 11.1% | ||
| Q2 24 | 3.7% | 9.9% | ||
| Q1 24 | 14.8% | -3.3% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | -4.4% | ||
| Q2 25 | 4.0% | -2.3% | ||
| Q1 25 | 8.0% | 0.2% | ||
| Q4 24 | -5.4% | -40.3% | ||
| Q3 24 | -16.3% | 1.6% | ||
| Q2 24 | -1.7% | 0.9% | ||
| Q1 24 | 13.2% | -8.5% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | $-0.24 | ||
| Q2 25 | $0.36 | $-0.12 | ||
| Q1 25 | $0.69 | $0.01 | ||
| Q4 24 | $-0.45 | $-2.81 | ||
| Q3 24 | $-1.27 | $0.09 | ||
| Q2 24 | $-0.14 | $0.05 | ||
| Q1 24 | $0.82 | $-0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $60.9M |
| Total DebtLower is stronger | — | $2.0B |
| Stockholders' EquityBook value | $540.7M | $470.7M |
| Total Assets | $1.4B | $2.9B |
| Debt / EquityLower = less leverage | — | 4.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | $60.9M | ||
| Q2 25 | $217.8M | $54.1M | ||
| Q1 25 | $149.8M | $61.2M | ||
| Q4 24 | $144.9M | $50.6M | ||
| Q3 24 | $145.0M | $54.7M | ||
| Q2 24 | $240.1M | $40.3M | ||
| Q1 24 | $228.6M | $42.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | $540.7M | — | ||
| Q3 25 | $505.8M | $470.7M | ||
| Q2 25 | $436.8M | $501.4M | ||
| Q1 25 | $418.6M | $513.1M | ||
| Q4 24 | $403.7M | $524.8M | ||
| Q3 24 | $405.9M | $755.3M | ||
| Q2 24 | $455.8M | $765.0M | ||
| Q1 24 | $452.0M | $781.2M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $2.9B | ||
| Q2 25 | $1.3B | $2.9B | ||
| Q1 25 | $1.3B | $3.0B | ||
| Q4 24 | $1.3B | $3.0B | ||
| Q3 24 | $1.3B | $3.4B | ||
| Q2 24 | $920.8M | $3.4B | ||
| Q1 24 | $914.5M | $3.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | 4.30× | ||
| Q2 25 | — | 3.97× | ||
| Q1 25 | — | 3.91× | ||
| Q4 24 | — | 3.85× | ||
| Q3 24 | — | 2.75× | ||
| Q2 24 | — | 2.67× | ||
| Q1 24 | — | 2.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-64.6M |
| Free Cash FlowOCF − Capex | $29.1M | $-70.7M |
| FCF MarginFCF / Revenue | 11.8% | -16.1% |
| Capex IntensityCapex / Revenue | 0.5% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $54.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | — | ||
| Q3 25 | $44.1M | $-64.6M | ||
| Q2 25 | $75.8M | $17.8M | ||
| Q1 25 | $35.0M | $52.7M | ||
| Q4 24 | $15.9M | $80.3M | ||
| Q3 24 | $12.5M | $4.2M | ||
| Q2 24 | $17.4M | $11.3M | ||
| Q1 24 | $18.3M | $35.1M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | $-70.7M | ||
| Q2 25 | $71.8M | $11.5M | ||
| Q1 25 | $32.5M | $42.4M | ||
| Q4 24 | $13.5M | $71.7M | ||
| Q3 24 | $7.7M | $-679.0K | ||
| Q2 24 | $13.0M | $5.2M | ||
| Q1 24 | $13.7M | $27.5M |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | -16.1% | ||
| Q2 25 | 34.0% | 2.7% | ||
| Q1 25 | 16.5% | 10.0% | ||
| Q4 24 | 7.1% | 13.0% | ||
| Q3 24 | 5.2% | -0.1% | ||
| Q2 24 | 9.4% | 1.2% | ||
| Q1 24 | 10.0% | 5.8% |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | 1.4% | ||
| Q2 25 | 1.9% | 1.5% | ||
| Q1 25 | 1.3% | 2.4% | ||
| Q4 24 | 1.3% | 1.6% | ||
| Q3 24 | 3.2% | 1.0% | ||
| Q2 24 | 3.2% | 1.4% | ||
| Q1 24 | 3.3% | 1.6% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | 63.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.56× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
BGS
| Specialty Segment | $150.5M | 34% |
| Meals Segment | $110.0M | 25% |
| Spices And Flavor Solutions Segment | $101.4M | 23% |
| Frozen And Vegetables Segment | $77.4M | 18% |
